International Journal of Biochemistry and Cell Biology 113 (2019) 115–116

Contents lists available at ScienceDirect

International Journal of Biochemistry and Cell Biology

journal homepage: www.elsevier.com/locate/biocel

Corrigendum

Corrigendum to "Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma" [Int. J. Biochem. Cell Biol. 108 (2019) 98–110]

Biqiang Zhu[a,b], Lei Zhao[a], Yang Liu[a], Ye Jin[a], Jing Feng[a], Fuya Zhao[a], Jiayu Sun[a], Rui Geng[a], Yunwei Wei[a,*]

[a] Department of Oncological and Endoscopic Surgery, The First Affiliated Hospital of Harbin Medical University, No. 23 You Zheng Street, Harbin 150001, Heilongjiang, China

[b] Translational Medicine Research and Cooperation Center of Northern China, Harbin 150081, Heilongjiang, China

The authors regret < in Fig. 2A of this paper, the image of the control group (0 uM) was incorrectly placed. The corrected version is shown below > .

The authors would like to apologise for any inconvenience caused.

Fig. 2: Evodiamine induced apoptosis in CCA cells.

The pro-apoptosis effects of evodiamine on TFK-1 cells (A) Apoptosis was assessed using Hoechst 33258, and apoptotic features were assessed by observing chromatin condensation and fragment staining (original magnification, × 200) (B) Detection of apoptosis via Annexin V/PI staining (X-axis: annexin V; Y-axis: PI) and analyzed by flow cytometry. (C & D) The protein levels of cleaved-caspase-3, cleaved-caspase-9, Bcl-2 and Bax were measured by Western blot. β-actin served as the loading control. The data are expressed as the mean SD of 3 replicate experiments. Significant differences from the control are indicated by $*P < 0.05$, $**P < 0.01$, $***P < 0.001$.

DOI of original article: https://doi.org/10.1016/j.biocel.2019.01.012

* Corresponding author.

E-mail address: hydwyw11@hotmail.com (Y. Wei).

https://doi.org/10.1016/j.biocel.2019.03.008

Available online 23 March 2019


A
0 uM
20 uM
40 uM
Percentage of apoptotic cells/fields (%)
Evodiamine (uM)
B
0 uM
20 uM
40 uM
Q1 0.850%
Q2 1.97%
Q4 92.6%
Q3 4.59%
Q1 1.18%
Q2 5.13%
Q4 82.5%
Q3 11.2%
Q1 2.82%
Q2 11.6%
Q4 71.1%
Q3 14.5%
Apoptotic cells (%)
Evodiamine (uM)
C
Evodiamine 0 10 20 40 uM
Cleaved caspase 3
Cleaved caspase 9
β-actin
0 uM
10 uM
20 uM
40 uM
Relative expression
Cleaved caspase 3
Cleaved caspase 9
D
Evodiamine 0 10 20 40 uM
Bax
Bcl-2
β-actin
Relative expression
Bax
Bcl-2